Compare Ishares Msci Brazil ETF (EWZ) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs Medpace Holdings Inc — how do they compare? Ishares Msci Brazil ETF trades at $43.48 (market cap $11.30B), while Medpace Holdings Inc trades at $617.56 (market cap $16.82B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 44,036,597). Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Brazil ETF for 50 Days and Medpace Holdings Inc for 14 Days on average.
| EWZ | MEDP | |
|---|---|---|
Market Cap | $11.30B | $16.82B |
Volume | 44,036,597 | 223,093 |
Sector | Broad Market / Factor | Health |
52-Week High | $43.00 | $630.19 |
52-Week Low | $28.79 | $393.42 |
Typical Hold Time | 50 Days | 14 Days |
Enterprise Value | — | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, trades at $43.14, up 1.82% with strong bullish momentum from moving averages but overbought RSI signals. The ETF shows unusual options activity and institutional interest, driven by Brazil's upcoming election and commodity exposure. Recent news highlights Wall Street positioning for potential policy shifts under different election outcomes, with the fund serving as a diversification tool from U.S. tech concentration.
Outlook remains election-dependent with asymmetric upside potential through call options. Risks include political volatility, U.S.-Brazil trade tensions, and currency fluctuations. The technical setup suggests near-term consolidation near pivot points while fundamentals rely on Brazil's economic policies and commodity performance.
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
